WO2011093294A1 - セファロスポリン誘導体の製造方法 - Google Patents
セファロスポリン誘導体の製造方法 Download PDFInfo
- Publication number
- WO2011093294A1 WO2011093294A1 PCT/JP2011/051390 JP2011051390W WO2011093294A1 WO 2011093294 A1 WO2011093294 A1 WO 2011093294A1 JP 2011051390 W JP2011051390 W JP 2011051390W WO 2011093294 A1 WO2011093294 A1 WO 2011093294A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- represented
- cephem
- carboxylic acid
- alkali metal
- Prior art date
Links
- 0 *C(C(c1c[s]c(N)n1)=C(*)O*)=O Chemical compound *C(C(c1c[s]c(N)n1)=C(*)O*)=O 0.000 description 2
- NNZIRGSJYSTRIH-ICACFTHWSA-N C[C@@H]([C@H]1SCC(/C=C\c2c(C)nc[s]2)=C(C(O)=O)N11)C1=O Chemical compound C[C@@H]([C@H]1SCC(/C=C\c2c(C)nc[s]2)=C(C(O)=O)N11)C1=O NNZIRGSJYSTRIH-ICACFTHWSA-N 0.000 description 1
- SDEIKNWRVHSKQN-FSZPXCJPSA-N Cc1c(/C=C\C(CS[C@@H]2[C@@H]3N)=C(C(O)=O)N2C3=O)[s]cn1 Chemical compound Cc1c(/C=C\C(CS[C@@H]2[C@@H]3N)=C(C(O)=O)N2C3=O)[s]cn1 SDEIKNWRVHSKQN-FSZPXCJPSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/04—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
- C07D501/06—Acylation of 7-aminocephalosporanic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
Definitions
- the present invention relates to a method for producing a cephalosporin derivative and an alkali metal salt thereof in which the content of the Z isomer is improved compared to the E isomer.
- this method of synthesizing cefditorene includes a compound represented by the following general formula (A) as shown in the following reaction scheme (1) and a 7-amino-3-[(Z ) -2- (4-Methylthiazol-5-yl) vinyl] -3-cephem-4-carboxylic acid or its alkali metal salt has been proposed (for example, see Patent Document 1). ).
- R 1 in the formula needs to use a protected amino group. Is inevitably necessary, and the process becomes complicated, which is not industrially advantageous.
- compound (2) 7-amino-3- [2- (4-methylthiazol-5-yl) vinyl] -3-cephem-4-carboxylic acid or an alkali metal salt thereof (compound (2)) is a cephalosporin antibiotic. It is a substance useful as a production intermediate. In this compound, there are two types of isomers, that is, the steric structure of the alkenyl group at the 3-position is a Z configuration and an E configuration. Among these two types of isomers, cephalosporin antibiotics using them as a raw material are known to have excellent antibacterial action as a pharmaceutical antibacterial agent, including the above-mentioned cefditoren, Z form. .
- Patent Document 2 7-amino-3- [2- (4-methylthiazol-5-yl) vinyl] -3-cephem-4-carboxylic acid in which Z and E isomers are mixed or It has been proposed that a high porous polymer or activated carbon is allowed to act on the aqueous solution of the alkali metal salt to increase the content of the Z-form.
- the high porous polymer used in this method include acrylic resins, phenolic resins, and styrene resins.
- the activated carbon general activated carbon such as zinc chloride charcoal or steam charcoal is used.
- an object of the present invention is to provide a method for producing a cephalosporin derivative or an alkali metal salt thereof that can eliminate the various disadvantages of the above-described prior art.
- the present invention relates to 7-amino-3-[(E / Z) -2- (4-methylthiazol-5-yl) vinyl] -3-cephem-4-carboxylic acid represented by the following formula (1):
- An aqueous solution of the alkali metal salt is brought into contact with activated carbon having an iodine adsorption performance measured in accordance with JIS K-1474 of 1200 mg / g or more and a methylene blue adsorption performance of 250 ml / g or more, and is represented by the following formula (2).
- 7-amino-3-[(E / Z) -2- (4-methylthiazol-5-yl) vinyl] -3-cephem-4-carboxylic acid or an alkali metal salt thereof is used.
- the objective cephalosporin derivative or alkali metal salt thereof having a high Z-form content can be provided by an industrially advantageous method in a simple process.
- a specific activated carbon is allowed to act on the compound represented by the above formula (1) including the Z-form and the E-form or an alkali salt thereof, and the E-form is selected for the activated carbon. It is characterized by the fact that it is removed by adsorption and the content of the Z body is increased.
- the alkali salt here means a pharmacologically acceptable alkali salt.
- the compound represented by the formula (1) and its alkali metal salt are collectively referred to as “alkenyl cephem compound”.
- the alkenyl cephem compound used in the present invention consists of a mixture of Z-form and E-form. Both Z-form and E-form are known compounds. There is no particular limitation on the abundance ratio of the Z form and the E form in the alkenyl cephem compound, and this abundance ratio depends on the production conditions of the alkenyl cephem compound. In view of the object of the present invention, it is desirable that the abundance ratio of the Z isomer is sufficiently higher than the abundance ratio of the E isomer. However, by using the method of the present invention, the Z isomer can be obtained easily and with a high yield. Is possible.
- the abundance ratio of the E form in the alkenyl cephem compound is expressed by the content calculated based on the calculation formula for the E form content used in the examples described later, and is generally 0.3 to 20% in the state before the treatment with activated carbon. In particular, it is 2 to 12%.
- the alkenyl cephem compound is brought into contact with activated carbon in the form of an aqueous solution.
- the alkenyl cephem compound may be treated with an alkali to form a corresponding salt (for example, an alkali metal salt).
- the alkali include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide and lithium hydroxide; alkali metal hydrogen carbonates such as sodium hydrogen carbonate; alkali metal carbonates such as sodium carbonate, potassium carbonate and lithium carbonate; Can be used.
- the pH of the aqueous solution may be in a high pH range such that the salt of the alkenyl cephem compound does not crystallize and precipitate, and is generally 7.1 to 9.0, particularly 7.5 to 8.5. It is preferable to use an alkali region.
- the concentration of the salt of the alkenyl cephem compound contained in the aqueous solution is not critical in the present invention, and may be a low concentration that does not cause the salt crystals to precipitate.
- the alkenyl cephem compound As another method for making the alkenyl cephem compound into an aqueous solution, there is a method of treating the alkenyl cephem compound with a mineral acid to form a corresponding mineral acid salt.
- the mineral acid include hydrochloric acid, sulfuric acid, nitric acid and the like.
- the pH of the aqueous solution containing the mineral acid salt may be in a low pH region so that the mineral acid salt does not precipitate, and is generally 0.5 to 1.7, particularly 0.8 to 1.4. It is preferable to do. Further, the concentration of the mineral acid salt contained in the aqueous solution is not critical in the present invention, and may be any level as long as the mineral acid salt does not precipitate.
- the alkali metal salt and the mineral acid salt are compared, it is preferable to use the mineral acid salt.
- the mineral acid salt the use of hydrochloride is particularly preferable because the purity of the Z form can be further increased.
- activated carbon treatment when activated carbon treatment, if phenylacetic acid or its derivative is present in the system, activated carbon is more likely to adsorb phenylacetic acid or its derivative than E-form.
- the amount of expensive activated carbon used can be reduced. This is particularly preferable from the viewpoint of further increasing the purity.
- the present inventors diligently investigated activated carbon for selectively adsorbing and removing E-forms from alkenyl cephem compounds, and it is effective to use activated carbon having a large pore diameter peak and a small pore diameter peak. found. Furthermore, as the inventors proceeded with investigations, activated carbon having such a pore size distribution has been identified with iodine adsorption performance measured according to JIS K-1474 and methylene blue adsorption performance measured according to JIS K-1474. It was found to be within the range. In the present invention, by using activated carbon having such specific iodine adsorption performance and methylene blue adsorption performance, it is possible to selectively adsorb and remove E form from the alkenyl cephem compound.
- the upper limit of iodine adsorption performance of activated carbon used in the present invention is 1700 mg / g. g. Therefore, the range of iodine adsorption performance is preferably 1200 to 1700 mg / g, and more preferably 1400 to 1700 mg / g.
- the higher the value of iodine adsorption performance the better. Therefore, there is no problem in using activated carbon having an iodine adsorption performance of more than 1700 mg / g.
- the methylene blue adsorption performance those having a value of 250 ml / g or more are used.
- the upper limit of the methylene blue adsorption performance of the activated carbon used in the present invention is 500 ml / g.
- the range of methylene blue adsorption performance is preferably 250 to 500 ml / g, more preferably 260 to 500 ml / g.
- the higher the value of the methylene blue adsorption performance the better. Therefore, there is no problem in using activated carbon having a methylene blue adsorption performance of more than 500 ml / g.
- the physical properties of activated carbon used in water treatment, etc. have iodine adsorption performance of 1200 mg / g or less and methylene blue adsorption performance of 200 ml / g or less (“Applied technology of activated carbon”, supervised by Hideki Tachimoto, Kunio Abe , Issuer Techno System Co., Ltd., date of issue July 25, 2000, pages 409 and 555), these physical properties of the activated carbon used in the present invention are much higher than those of ordinary activated carbon. It is expensive. This is because large pores and small pores are distributed.
- iodine adsorption performance is an indicator of small pore distribution (that is, an index of adsorptivity of a compound having a low molecular weight)
- methylene blue adsorption performance is an indicator of distribution of a large pore (that is, an adsorptivity of a compound having a large molecular weight). Index).
- Examples of the activated carbon satisfying the above-mentioned iodine adsorption performance and methylene blue adsorption performance include, for example, water vapor activated activated carbon using coconut shell, coal, wood material and the like as raw materials.
- the above-described physical property values are satisfied by appropriately controlling the activation conditions and appropriately controlling the granulation conditions.
- the activated carbon may be in the form of powder, granules or fibers, or may be a molded body. It is also possible to use a commercial product as activated carbon that satisfies the above physical property values.
- Unitika activated carbon fiber Adol A-20 (trade name), which is activated carbon available from Unitika Ltd.
- Liquid Phase Activated Carbon CL-KP activated carbon, available from Ajinomoto Fine Techno) Name
- CL-K trade name
- the method for bringing the above-mentioned activated carbon into contact with the alkenyl cephem compound there is no particular limitation on the method for bringing the above-mentioned activated carbon into contact with the alkenyl cephem compound.
- a method of adding the above-mentioned activated carbon to an aqueous solution of an alkenyl cephem compound, or a method of adding an aqueous solution of an alkenyl cephem compound to the above-mentioned activated carbon can be employed.
- the above-mentioned activated carbon is packed in a column, and an aqueous solution of the alkenyl cephem compound is fed to the column with a pump or the like, passed through the column, and further circulated through the column a plurality of times, or activated carbon is applied to a molded body such as a filter.
- a method in which an aqueous solution of the alkenyl cephem compound is brought into contact with the contained one can also be adopted.
- the ratio between the amount of activated carbon and the amount of alkenyl cephem compound is not particularly limited.
- activated carbon is 10 to 300 parts by weight, particularly 10 to 200 parts by weight with respect to 100 parts by weight of alkenyl cephem compound contained in the aqueous solution. It is preferable to make it contact from the point which can reduce the loss rate of Z body and can remove E body and phenylacetic acid efficiently.
- the temperature at the time of contact can be 0 to 20 ° C. By making the temperature at the time of contact within this range, the loss rate of the Z form can be reduced, and the E form and phenylacetic acid can be efficiently removed, which is preferable.
- the contact time is preferably 0.5 to 3 hours, particularly 1 to 2 hours, provided that the temperature at the time of contact is in the above range. While the two are in contact with each other, the reaction system may be in a stirred state or may be left in a stationary state.
- the above method may be performed only once, or may be repeated two or more times for the purpose of increasing the purity of the Z form.
- the E-form is selectively adsorbed and removed from the alkenyl cephem compound including the Z-form and the E-form by activated carbon, and the content of the Z-form increases.
- the activated carbon and the treatment liquid are separated, and acid such as hydrochloric acid, nitric acid, sulfuric acid (when made water-soluble with alkali) or alkali such as sodium hydroxide (when made water-soluble with mineral acid) is added to the treatment liquid.
- the pH of the solution is adjusted to a weakly acidic region of 3.8 to 4.8 to precipitate crystals of the compound represented by formula (2).
- the obtained crystals are separated by filtration or centrifugation, and washed with water and an organic solvent such as methanol.
- the content of the Z isomer is improved as a target product with high purity and high yield. It can be recovered as a compound represented by the formula (1).
- an alkenylcephem compound used as a starting material is, for example, a 7-substituted acylamino-3-[(E / Z) -2- (4-methylthiazol-5-yl) represented by the following formula (6). It can be obtained by subjecting a salt of vinyl] -3-cephem-4-carboxylic acid to an enzyme reaction to deprotect the amide bond at the 7-position. If this salt is water-soluble, there will be no restriction
- R 3 represents a benzyl group or a phenoxymethyl group.
- M represents a monovalent cation.
- the solvent for the enzyme reaction water is preferably used from the viewpoint of maximizing enzyme activity.
- the pH of the enzyme reaction is a factor that affects the activity of the enzyme. Although depending on the type of enzyme, it is preferable to maintain the pH at 7.5 to 8.5 from this viewpoint.
- Various alkali aqueous solutions for example, alkali metal hydroxides such as sodium hydroxide and potassium hydroxide; alkali metal hydrogen carbonates such as sodium hydrogen carbonate; alkali metal carbonates such as sodium carbonate and potassium carbonate; An aqueous solution can be used.
- the temperature of the enzyme reaction is also a factor that affects the activity of the enzyme. Although depending on the type of enzyme, the temperature of the reaction system is preferably maintained at 25 to 35 ° C. from this viewpoint.
- the reaction time is not critical in the present invention. In general, the reaction may be performed until the compound represented by formula (6) disappears from the reaction system. The reaction time can be generally 1 to 3 hours, provided that the pH and temperature are within the above-mentione
- a conventionally known penicillin G acylase can be used without particular limitation.
- Penicillin G amidase PGA-150, PGA-300, PGA-450 manufactured by Boehringer Mannheim; Penicillin G acylase manufactured by Dallas Biotech Limited; Penicillin G amidase manufactured by Roche Molecular Biochemicals; Biological Technology Co., Ltd. IPA-750; Atlas Biologics Co., Ltd. SynthaCLEC-PA, etc. can be used.
- the amount of the enzyme used is preferably 30 to 150 parts by weight, particularly 50 to 100 parts by weight, based on 100 parts by weight of the compound represented by the formula (6), although it depends on the type.
- the salt of the alkenyl cephem compound is obtained by the above enzymatic reaction.
- phenylacetic acid or a derivative thereof (hereinafter collectively referred to as “phenylacetic acids”) is a by-product by deprotection of the amide protecting group at the 7-position in the compound represented by formula (6).
- phenylacetic acids a by-product by deprotection of the amide protecting group at the 7-position in the compound represented by formula (6).
- phenylacetic acids is a by-product by deprotection of the amide protecting group at the 7-position in the compound represented by formula (6).
- Generate as This phenylacetic acid or the like is a 7-amino-3- [2- (4-methylthiazol-5-yl) vinyl] -3-cephem-4-carboxylic acid having a high content of Z form, which is an object of this production method Since it is an impurity with respect to an acid, in the present invention, it is necessary to eliminate
- the method for removing phenylacetic acid before the second step can be carried out by performing any of the following steps before or after the contact between the alkenyl cephem compound and activated carbon.
- A Before contacting the alkenyl cepham compound represented by the formula (1) with activated carbon, the aqueous solution of the alkenyl cepham compound represented by the formula (1) is used in an aqueous solution of the phenylacetic acid. A process of performing an extraction process.
- a crystallization treatment for precipitating the alkenyl cephem compound from an aqueous solution of the alkenyl cephem compound represented by formula (1) is performed before contacting the activated carbon with the alkenyl cephem compound represented by formula (1). Process.
- the pH of the aqueous salt solution of the compound represented by the formula (1) obtained by the enzyme reaction is adjusted to an acidic range by mineral acid. It is preferable to adjust the salt of the compound represented by the formula (1) in the aqueous solution to the form of the corresponding mineral acid salt by adjusting it to 2 or less, particularly 1 or less.
- the mineral acid include hydrochloric acid, nitric acid, sulfuric acid and the like.
- organic solvent used for the extraction treatment examples include (a) lower alkyl esters of lower carboxylic acids, (b) ketones, (c) ethers, (d) substituted or unsubstituted aromatic hydrocarbons, ) Halogenated hydrocarbons, (f) aliphatic hydrocarbons, and (g) cycloalkanes. These organic solvents can be used alone or in combination of two or more.
- Examples of the lower alkyl esters of the lower carboxylic acid (i) include methyl formate, ethyl formate, propyl formate, butyl formate, methyl acetate, ethyl acetate, propyl acetate, butyl acetate, methyl propionate, and ethyl propionate.
- Examples of (b) ketones include methyl propyl ketone, methyl butyl ketone, methyl isobutyl ketone, and diethyl ketone.
- Examples of (iii) ethers include diethyl ether, ethyl propyl ether, ethyl butyl ether, dipropyl ether, diisopropyl ether, dibutyl ether, methyl cellosolve, dimethoxyethane and the like.
- Examples of the substituted or unsubstituted aromatic hydrocarbons of (d) include benzene, toluene, xylene, chlorobenzene, anisole and the like.
- halogenated hydrocarbons of (e) include dichloromethane, chloroform, dichloroethane, trichloroethane, dibromoethane, propylene dichloride, carbon tetrachloride and the like.
- Aliphatic hydrocarbons pentane, hexane, heptane, octane and the like.
- (g) cycloalkanes include cyclopentane, cyclohexane, cycloheptane, cyclooctane and the like.
- organic solvents those having a solubility in water at 20 ° C. of 1% by weight or less, specifically, toluene, chloroform, chlorobenzene and the like are preferable, and toluene is particularly preferable.
- an organic solvent having high polarity and high solubility in water When an organic solvent having high polarity and high solubility in water is used, the organic solvent is dissolved in the aqueous solution of the alkenyl cephem compound to be extracted.
- an aqueous solution of an alkenyl cephem compound in which an organic solvent is dissolved is subjected to the above-described treatment with activated carbon, the activated carbon adsorbs the organic solvent, so that the E-adsorption removal efficiency is reduced and the purity of the Z-form is improved. It becomes difficult. Therefore, when an organic solvent having high solubility in water is used, a concentration step is required to concentrate the aqueous solution after the extraction treatment and remove the organic solvent from the aqueous solution before performing the treatment with activated carbon.
- Use of an organic solvent having a low solubility of 1% by weight or less at 20 ° C. in water is industrially advantageous because a concentration step is unnecessary.
- organic solvents are preferably used in an amount of 5 to 50 liters, more preferably 10 to 30 liters per kg of the alkenyl cephem compound in the aqueous solution.
- the extraction treatment is preferably performed at 0 to 20 ° C. If it is this preferable ratio, the content rate of phenylacetic acids can be reduced efficiently in an extraction process.
- phenylacetic acids are represented by the content calculated based on the formula for calculating the phenylacetic acid content used in the examples described later, and reduced to 8% or less. It is preferable to make it. By repeating the extraction process a plurality of times, the content of phenylacetic acid gradually decreases. Therefore, if the content of phenylacetic acid does not become 8% or less in one extraction process, the solvent extraction may be performed a plurality of times. preferable.
- the aqueous solution that has been extracted with the organic solvent can be directly brought into contact with activated carbon.
- the pH of the aqueous salt solution of the compound represented by the formula (1) obtained by the enzyme reaction is weakly acidic with a mineral acid.
- the salt of the compound represented by the formula (1) in the aqueous solution is precipitated as a free form by adjusting to a range, specifically 3.5 to 4.8, particularly 3.5 to 4.5. Make it easy.
- pH adjustment can be performed by adding mineral acids, such as hydrochloric acid, nitric acid, and a sulfuric acid, to this aqueous solution.
- the compound represented by the formula (1) in the aqueous solution can be precipitated by maintaining the aqueous solution at preferably 20 ° C. or lower, more preferably 1 to 10 ° C.
- the crystallization treatment may be performed under stirring or standing.
- the compound represented by formula (1), which is a precipitate, is solid-liquid separated by a conventional method and recovered from a treatment liquid containing phenylacetic acids.
- the phenylacetic acids are represented by the content calculated based on the calculation formula for the content of phenylacetic acid used in the examples described later, and are up to 8% or less. It is preferable to reduce. Since the crystallization treatment has higher separation and removal efficiency of phenylacetic acids than the extraction treatment of (A), the crystallization treatment can be performed in one crystallization treatment under the conditions of pH 4.8 or less and 20 ° C. or less. It is possible to reduce the content of phenylacetic acids to 2% or less.
- the crystallization treatment is preferably performed a plurality of times.
- the precipitate (compound represented by formula (1)) obtained in the treatment step is dissolved in water to form an aqueous solution, and the aqueous solution is brought into contact with activated carbon.
- the processing step (C) Prior to recovering the compound represented by the formula (2) by the precipitation operation after the above-mentioned activated carbon treatment and recovering it as the compound of the formula (1) in which the content of the Z-form is improved, in the treatment liquid treated with the activated carbon.
- the contained phenylacetic acid is extracted with an organic solvent.
- the activated carbon and the treatment liquid are separated, and an acid (when made water-soluble with alkali) or alkali (when made water-soluble with mineral acid) is added to the treatment liquid, and the pH of the liquid is preferably 2 or less More preferably, the solvent is extracted from this aqueous solution using an organic solvent.
- the concentration of phenylacetic acids in the treatment liquid gradually decreases.
- the same solvent as in the step (A) can be used. Specifically, (a) lower alkyl esters of lower carboxylic acids, (b) ketones, (c) ethers, (d) substituted or unsubstituted aromatic hydrocarbons, (e) halogenated hydrocarbons , (F) aliphatic hydrocarbons, and (g) cycloalkanes. These organic solvents can be used alone or in combination of two or more.
- Examples of the lower alkyl esters of the lower carboxylic acid (i) include methyl formate, ethyl formate, propyl formate, butyl formate, methyl acetate, ethyl acetate, propyl acetate, butyl acetate, methyl propionate, and ethyl propionate.
- Examples of (b) ketones include methyl propyl ketone, methyl butyl ketone, methyl isobutyl ketone, and diethyl ketone.
- Examples of (iii) ethers include diethyl ether, ethyl propyl ether, ethyl butyl ether, dipropyl ether, diisopropyl ether, dibutyl ether, methyl cellosolve, dimethoxyethane and the like.
- Examples of the substituted or unsubstituted aromatic hydrocarbons of (d) include benzene, toluene, xylene, chlorobenzene, anisole and the like.
- halogenated hydrocarbons of (e) include dichloromethane, chloroform, dichloroethane, trichloroethane, dibromoethane, propylene dichloride, carbon tetrachloride and the like.
- Aliphatic hydrocarbons pentane, hexane, heptane, octane and the like.
- (g) cycloalkanes include cyclopentane, cyclohexane, cycloheptane, cyclooctane and the like.
- the concentration of phenylacetic acid is represented by the content calculated based on the phenylacetic acid content calculation formula used in the examples described later, and is preferably 8% or less. It becomes possible to reduce to.
- an alkali such as sodium hydrogen carbonate is added to the treatment liquid and isoelectric point precipitation is performed to precipitate crystals, which are collected.
- the processing step (A), the processing step (B), and the processing step (C) can be appropriately combined.
- which processing step is performed first is not particularly limited.
- the E-form is adsorbed and removed by the activated carbon, and at the same time, phenylacetic acids are also adsorbed.
- the amount of activated carbon used can be reduced.
- the amount of activated carbon is preferably 10 to 200 parts by weight, particularly 20 to 100 parts by weight, based on 100 parts by weight of the alkenyl cephem compound contained in the aqueous solution.
- the process process of the said (A) and the process process of (B) are preceded by an activated carbon process. Since the coloring component is also removed by performing, the compound represented by the formula (1) having an improved content of the Z isomer can reduce the coloration, and as a result, the final target formula (4a) or ( There is also an advantage that the cephalosporin derivative represented by 4b) is less colored.
- a by-product of the deprotection reaction produced by subjecting the salt of the compound represented by the formula (6) to an enzyme reaction to deprotect the 7-position amide bond. It is preferable to use an alkenylcephem compound containing phenylacetic acid or a derivative thereof as a raw material.
- the compound represented by the formula (6) can be synthesized by a known method.
- a compound represented by the formula (6) can be obtained by deprotecting the 4-position carboxylic acid protecting group.
- various methods known as a deprotection reaction of a carboxylic acid protecting group in a ⁇ -lactam compound can be employed.
- a deprotection reaction in phenols described in JP-A No. 61-263984 can be employed.
- R 3 is as defined above.
- R 4 represents a carboxylic acid protecting group.
- examples of the carboxylic acid protecting group represented by R 4 include a benzyl group optionally substituted with an electron donating group, a diphenylmethyl group optionally substituted with an electron donating group, and the like. Is mentioned.
- examples of the electron donating group include an alkyl group having 1 to 6 carbon atoms; a hydroxy group, and an alkoxy group having 1 to 6 carbon atoms.
- R 1 represents an alkyl group.
- the alkyl group include lower alkyl groups having 1 to 6 carbon atoms such as a methyl group, an ethyl group, a propyl group, and a butyl group.
- R 1 in the formula is particularly preferable because the methyl group can be directly derived into cefditorene.
- X represents an active ester group.
- the active ester group corresponding to X in the formula is, for example, an active ester group generated by a reaction between a compound represented by the following general formula (9) and a compound that introduces an active ester group into the compound of the formula (9).
- transduces is mentioned.
- Examples of the compound that introduces an active ester group into the compound of the formula (9) include thionyl chloride, oxalyl chloride, dicyclohexylcarbodiimide, bis- [benzothiazolyl- (2)] disulfide, 2-hydroxy-benzthiazole, 2-halo- N-methylpyridinium salt, thiophosphoric acid (for example, diethylthiophosphoric acid) and the like can be mentioned.
- X in the formula is a reaction residue of bis- [benzothiazolyl- (2)] disulfide, represented by the following formula (5
- the benzothiazolyl-2-thiol group represented by (II) is particularly preferred from the viewpoint of excellent reactivity with the purified alkenyl cepham compound and the desired product can be obtained in high yield.
- the reaction between the compound represented by the general formula (9) and the compound that introduces an active ester group into the compound of the formula (9) is a known reaction (for example, JP-A-58-152488 and (See JP-T-2006-507290).
- the compound represented by formula (3) is particularly preferably a compound in which R 1 is a methyl group and X is a benzothiazolyl-2-thiol group represented by formula (5). It is particularly preferable because it can be obtained in a yield and the compound itself is industrially available.
- the amount of the compound represented by the formula (3) added to the reaction system is 1.0 to 1.5, preferably 1.1 to 1.3 in terms of a molar ratio to the purified alkenyl cepham compound. Is preferable from the standpoint that can be obtained with high purity and high yield.
- the reaction according to the second step is performed in a solvent in the presence of a base.
- a base for example, organic bases such as triethylamine, tri-n-butylamine, tert-butylamine, dicyclohexylamine, N-methylmorpholine, 2,3-dimethylaminopyridine, N-methylpyrrolidone are preferably used.
- the addition amount of the base is 0.9 to 1.5, preferably 1.0 to 1.2 in terms of a molar ratio to the purified alkenyl cepham compound, whereby the target product can be obtained with high purity and high yield. From the viewpoint of being able to do so.
- Solvents that can be used include alcohols such as methanol, ethanol, 1-propanol, 2-propanol, butanol, water, acetone, acetonitrile, tetrahydrofuran, dichloromethane, dichloroethane, chloroform, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, ethyl acetate, propyl acetate
- a solvent such as n-butyl acetate is preferable, and these solvents are used as one or a mixture of two or more.
- the reaction temperature is ⁇ 10 to 40 ° C., preferably 0 to 20 ° C., and the reaction time is 2 hours or more, preferably 4 to 10 hours.
- the cephalosporin derivative represented by the above or its alkali metal salt can be obtained.
- the alkali metal salt of the formula (4a) means a pharmacologically acceptable alkali salt.
- cephalosporin derivative represented by the formula (4a) or the alkali metal salt thereof obtained in the present invention is made into a Z-form by providing a third step of reacting with chloromethyl bivalinate in the presence of sodium iodide.
- the method for analyzing the content of phenylacetic acid is as follows. Column: SUPELCO ODS HYPERSIL 5 ⁇ m 250 ⁇ 4.6 mm -Column temperature: 25 ° C Mobile phase (volume ratio): acetonitrile 20%, 50 mM potassium dihydrogen phosphate aqueous solution 80% ⁇ Flow rate: 1.0ml / min ⁇ Detection wavelength: 225 nm ⁇ Injection volume: 10 ⁇ l -Z-form + E-form retention time: 2.5-3.5 minutes- Phenylacetic acid retention time: 8.5-9.5 minutes- Phenylacetic acid content (calculation formula): [Phenylacetic acid area value / ((Z + E) body area value + phenylacetic acid area value)] ⁇ 100 (%)
- Example 1 (1) Deprotection reaction step of 7-position amide bond A 10.0 g four-necked flask was weighed with a compound represented by the following formula (10) (content of E-form: 3.5%), and 6% by weight sodium bicarbonate An aqueous solution of sodium salt was obtained by adding 240 g of an aqueous solution. To this aqueous solution, 7.0 g of penicillin-G acylase enzyme (PGA-450, manufactured by Dalas Biotech Limited) was added. The 7-position deprotection reaction of the sodium salt of the compound represented by the formula (10) was carried out while adding a 5 wt% aqueous sodium carbonate solution at a liquid temperature of 25 to 35 ° C.
- PGA-450 penicillin-G acylase enzyme
- the aqueous solution contained 7.0 g of a sodium salt of a compound represented by the following formula (11) containing 3.5% of E form in terms of E form. Further, phenylacetic acid was contained at 16.6% in terms of phenylacetic acid content.
- step A The enzyme (PGA-450) was filtered off from the aqueous solution obtained in the first step, and concentrated hydrochloric acid was added while maintaining the liquid temperature at 0 to 10 ° C. to adjust the pH of the aqueous solution to 0.9.
- the sodium salt of the compound represented by the formula (11) contained therein was used as the hydrochloride of the compound represented by the formula (11).
- the aqueous solution whose pH was adjusted was transferred to a separatory funnel, and 150 ml of toluene was added thereto to extract and remove by-products and impurities while maintaining the liquid temperature at 20 ° C.
- the phenylacetic acid content after the extraction treatment was 6.1%.
- the concentration of the alkenyl cephem compound in the aqueous solution after the extraction treatment was 2.2% by weight.
- Z body yield (%) A ⁇ B / C A: Crude yield (%) of crystals obtained after the first step B: Purity (%) of the compound represented by formula (2) as Z-form C: Theoretical yield (%) of the Z form of the compound represented by the formula (1) based on the mineral acid salt of the compound represented by the formula (11) in the phenylacetic acid removal step (result of analysis) -Z body yield: 92.0% -E body content: 0.29% ⁇ Phenylacetic acid content: 0.1% -Color tone (visual): White- 1 H-NMR (D 2 O / DCl) ppm 2.52 (s, 3H), 3.56 to 3.60 (d, 1H, 18.3 Hz), 3.75 to 3.78 (d, 1H, 18.6 Hz), 5.25 to 5.26 (d , 1H, 5.2Hz), 5.44-5.45 (d, 1H, 5.2Hz), 6.78 (s, 2H), 9.78 (s, 1H)
- Example 2 In the first step of Example 1, a compound represented by the formula (11) was obtained in the same manner as in Example 1 except that 2.8 g of CL-KP (trade name) manufactured by Ajinomoto Fine Techno was used as the activated carbon. Crystal was obtained. The activated carbon had an iodine adsorption performance of 1620 mg / g and a methylene blue adsorption performance of 280 ml / g.
- 40 g of 2.5% aqueous sodium hydrogen carbonate solution was added and washed twice with 80 g of dichloromethane, and the aqueous layer was concentrated. Concentration precipitated the sodium salt of the compound represented by formula (7).
- Table 1 shows various physical properties of the compound of the formula (11) obtained after completion of the first step
- Table 2 shows various physical properties of the cephalosporin derivative obtained after completion of the second step.
- Example 3 Deprotection reaction step of 7-position amide bond
- the enzyme reaction was carried out under the same operation and conditions as in Example 1. After completion of the reaction, the aqueous solution contained 7.0 g of a sodium salt of the compound represented by the formula (11) containing 3.5% of E form in terms of E form content. Further, phenylacetic acid was contained at 16.6% in terms of phenylacetic acid content.
- Phenylacetic acid removal step step B
- the enzyme (PGA-450) was filtered off from the aqueous solution obtained in the first step, adjusted to pH 4.2 with concentrated hydrochloric acid while keeping the liquid temperature at 10 ° C., and aged for 1 hour.
- activated carbon (Ajinomoto Fine Co., Ltd.) having iodine adsorption performance measured in accordance with JIS K-1474 of 1080 mg / g and methylene blue adsorption performance of 180 ml / g in place of the activated carbon used in the first step of Example 1 in this aqueous solution.
- 5.6 g of Techno SD, trade name SD-2 was added all at once and stirred at 3 ° C. for 1 hour.
- the phenylacetic acid content after the activated carbon treatment was 1.1%.
- the activated carbon was filtered off, and solvent extraction was performed on the obtained filtrate in the same manner as in the second step of Example 1.
- Example 4 (1) Third Step 4.5 g of the sodium salt of the compound represented by the formula (7) obtained in Example 2 is dissolved in 25 g of dimethylformamide (DMF), and chloromethyl pivalate (1.39 g) and iodine 25 ml of a DMF solution of iodomethyl pivalate prepared using sodium hydroxide (1.39 g) was added at 0-5 ° C., and the mixture was stirred at that temperature for 1 hour. Thereafter, 200 g of ethyl acetate was added to the reaction solution, and the mixture was washed 3 times with 100 g of water.
- DMF dimethylformamide
- 7-amino-3-[(E / Z) -2- (4-methylthiazol-5-yl) vinyl] -3-cephem-4-carboxylic acid or an alkali metal salt thereof is used.
- the objective cephalosporin derivative or alkali metal salt thereof having a high Z-form content can be provided by an industrially advantageous method in a simple process.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Cephalosporin Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
従来、このセフジトレンの合成方法は、下記反応スキーム(1)に示すように下記一般式(A)で表される化合物と、下記式(2)で表される7-アミノ-3-[(Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はそのアルカリ金属塩との反応により製造する方法が提案されている(例えば、特許文献1参照。)。
しかしながら、前記の反応スキーム(1)の方法では、目的とするセファロスポリン抗生物質を得るには式中のR1は保護されたアミノ基を用いる必要があり、このためアミノ保護基の除去工程が必然的に必要で、工程が複雑になり工業的に有利でない。
次いで、前記第1工程で得られた一般式(2)で表される7-アミノ-3-[(Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はそのアルカリ金属塩の含有率が向上した式(1)で表される7-アミノ-3-[(E/Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はそのアルカリ金属塩と、下記一般式(3)で表される化合物とを反応させる第2工程を含むことを特徴とする下記一般式(4a)で表されるセファロスポリン誘導体又はそのアルカリ金属塩の製造方法を提供することにより前記目的を達成したものである。
(式中、R1は、アルキル基を示す。Xは活性エステル基を示す。)
本発明に係る第1工程では、Z体とE体とが含まれる前記の式(1)で表される化合物又はそのアルカリ塩に、特定の活性炭を作用させて、該活性炭にE体を選択的に吸着させることで除去し、Z体の含有率を高める点に特徴を有する。ここで言うアルカリ塩とは、薬理学上許容されるアルカリ塩を意味する。なお、以下の説明においては、式(1)で表される化合物と、そのアルカリ金属塩を総称して、「アルケニルセフェム化合物」という。
(A)式(1)で表わされるアルケニルセファム化合物と活性炭の接触の前に、式(1)で表されるアルケニルセファム化合物の水溶液に対し、有機溶媒を用いて、前記フェニル酢酸類の抽出処理を行う工程。
(B)式(1)で表わされるアルケニルセファム化合物と活性炭の接触の前に、式(1)で表されるアルケニルセファム化合物の水溶液から、該アルケニルセフェム化合物を析出させる晶析処理を行う工程。
(C)式(1)で表わされるアルケニルセファム化合物と活性炭の接触の後、上述の析出操作によって式(2)で表される化合物を回収するに先立ち、有機溶媒を用いて、前記フェニル酢酸類の抽出処理を行う工程。
フェニル酢酸類の抽出除去を確実に行う観点から、抽出処理に先立ち、鉱酸により、前記酵素反応によって得られた式(1)で表される化合物の塩の水溶液のpHを酸性域、具体的には2以下、特に1以下に調整して、水溶液中の式(1)で表される化合物の塩を、対応する鉱酸塩の形態とすることが好ましい。該鉱酸としては、塩酸、硝酸、硫酸等が挙げられる。
前記(A)の処理工程後、有機溶媒による抽出処理を終えた水溶液を、そのまま活性炭と接触させることができる。
式(1)で表される化合物を析出させて収率よく回収する観点から、鉱酸により、前記酵素反応によって得られた式(1)で表される化合物の塩の水溶液のpHを弱酸性域、具体的には3.5~4.8、特に3.5~4.5に調整して、水溶液中の式(1)で表される化合物の塩を、フリーの形態として、析出しやすい状態にする。なお、pH調整は、塩酸、硝酸、硫酸などの鉱酸を該水溶液に添加することにより行うことができる。
次いで、該水溶液を好ましくは20℃以下、さらに好ましくは1~10℃に保持することにより、水溶液中の式(1)で表される化合物を析出させることができる。なお、晶析処理は攪拌下に行っても、静置下に行ってもよい。析出物である式(1)で表される化合物は、常法により固液分離して、フェニル酢酸類を含む処理液より回収する。
前記(B)の処理工程後は、該処理工程により得られた析出物(式(1)で表される化合物)を水に溶解して水溶液とし、該水溶液を活性炭と接触させる。
上述の活性炭処理後の析出操作によって式(2)で表される化合物を析出させZ体の含有率が向上した式(1)の化合物として回収するに先立ち、活性炭で処理された処理液中に含まれているフェニル酢酸類を有機溶媒により抽出する。具体的には、活性炭と処理液とを分離し、処理液に酸(アルカリで水溶性にした場合)又はアルカリ(鉱酸で水溶性にした場合)を加えて液のpHを好ましくは2以下、更に好ましくは1以下にし、有機溶媒を用いてこの水溶液からフェニル酢酸類を溶媒抽出する。溶媒抽出を複数回繰り返すことで、処理液中のフェニル酢酸類の濃度が次第に低下する。
また、上述の活性炭を、強酸性領域においてアルケニルセフェム化合物と接触させることで、該活性炭によってE体が吸着除去されるのと同時に、フェニル酢酸類も吸着されることから、活性炭処理に先だって、前記(A)工程及び/前記(B)工程を行うことにより、使用する活性炭の使用量を低減することができるという利点を有する。この場合、活性炭の使用量は、例えば、水溶液中に含まれるアルケニルセフェム化合物100重量部に対して、活性炭を10~200重量部、特に20~100重量部とすることが望ましい。
第1工程終了後、前記第1工程で得られたZ体の含有率が向上した式(1)で表される7-アミノ-3-[(E/Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はそのアルカリ金属塩と、前記一般式(3)で表される化合物とを反応させ、目的とする(4a)で表されるセファロスポリン誘導体又はそのアルカリ金属塩を得る。以下、Z体の含有率が向上した式(1)で表される7-アミノ-3-[(E/Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はそのアルカリ金属塩を総称して、「精製アルケニルセファム化合物」という。
この中、式中のR1はメチル基がそのままセフジトレンに誘導できることから特に好ましい。
(式中のR1は前記と同義。)
前記式(9)の化合物に活性エステル基を導入する化合物としては、例えば塩化チオニル、塩化オキサリル、ジシクロヘキシルカルボジイミド、ビス-〔ベンゾチアゾリル-(2)〕ジスルフィド、2-ヒドロキシ-ベンジチアゾール、2-ハロ-N-メチルピリジニウム塩、又はチオリン酸(例えば、ジエチルチオリン酸)等が挙げられ、特に好ましくは、式中のXはビス-〔ベンゾチアゾリル-(2)〕ジスルフィドの反応残基である下記式(5)で表わされるベンゾチアゾリル-2-チオール基が、精製アルケニルセファム化合物との反応性に優れ、また、目的物が高収率で得られる観点から特に好ましい。
なお、前記一般式(9)で表わされる化合物と、式(9)の化合物に活性エステル基を導入する化合物との反応は、公知の反応である(例えば、特開昭58-152488号公報及び特表2006-507290号公報参照。)。
使用できる塩基としては、例えば、トリエチルアミン、トリ-n-ブチルアミン、tert-ブチルアミン、ジシクロヘキシルアミン、N-メチルモルホリン、2,3-ジメチルアミノピリジン、N-メチルピロリドン等の有機塩基が好ましく用いられる。
塩基の添加量は、精製アルケニルセファム化合物に対するモル比で0.9~1.5、好ましくは1.0~1.2で行うことが、目的物を高純度で、且つ高収率で得ることができる観点から好ましい。
また、本発明で得られる式(4a)で表わされるセファロスポリン誘導体又はそのアルカリ金属塩は、ヨウ化ソーダの存在下にビバリン酸クロロメチルと反応させる第3工程を設けることにより、Z体の含有率の高い下記一般式(4b)
(式中、R1はアルキル基を示す。)で表されるセファロスポリン誘導体を製造することができ、特に式中のR1がメチル基である7-[2-メトキシイミノ-2-(2-アミノチアゾール-4-イル)アセトアミド]-3-[2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸ピバロイルオキシメチルエステル(セフジトレンピボキシル)はセファロスポリン抗生物質として有用な物質であることが知られている。
・カラム:Unison UK-C18、3μm、250mm×4.6mm
・カラム温度:30℃
・移動相(体積比):アセトニトリル13%、10mMへプタンスルホン酸ナトリウム水溶液87%
・流量:0.8ml/min
・検出波長:254nm
・注入量:10μl
・Z体保持時間:29.0~30.0分
・E体保持時間:31.0~32.0分
・E体含有率(計算式):〔E体面積値/(Z体面積値+E体面積値)〕×100(%)
・カラム:SUPELCO ODS HYPERSIL 5μm 250×4.6mm
・カラム温度:25℃
・移動相(体積比):アセトニトリル20%、50mMリン酸二水素カリウム水溶液80%
・流量:1.0ml/min
・検出波長:225nm
・注入量:10μl
・Z体+E体保持時間:2.5~3.5分
・フェニル酢酸保持時間:8.5~9.5分
・フェニル酢酸含有率(計算式):
〔フェニル酢酸面積値/((Z+E)体面積値+フェニル酢酸面積値)〕×100(%)
(1)7位アミド結合の脱保護反応工程
下記式(10)で表される化合物(E体の含有率3.5%)を10.0g四口フラスコにはかり取り、6重量%炭酸水素ナトリウム水溶液240gを加えてナトリウム塩の水溶液となした。この水溶液に、ペニシリン-Gアシラーゼ酵素(PGA-450、Dalas Biotech Limited製)を7.0g添加した。液温25~35℃、5重量%炭酸ナトリウム水溶液を添加して、pHを7.5~8.5に制御しながら式(10)で表される化合物のナトリウム塩の7位脱保護反応を2時間行った。反応終了後、水溶液中には、E体をE体含有率で3.5%含有する下記式(11)で表される化合物のナトリウム塩が7.0g含まれていた。また、フェニル酢酸がフェニル酢酸含有率で16.6%含まれていた。
第1工程で得られた水溶液から酵素(PGA-450)を濾別し、液温を0~10℃に保ちながら濃塩酸を添加して、水溶液のpHを0.9に調整し、水溶液に含まれていた式(11)で表される化合物のナトリウム塩を、式(11)で表される化合物の塩酸塩とした。pH調整が終了した水溶液を分液ロートに移し替え、液温を20℃に保ちながら、ここに150mlのトルエンを加えて副生成物及び不純物を抽出除去した。抽出処理後のフェニル酢酸含有率は6.1%であった。尚、抽出処理後の水溶液中のアルケニルセフェム化合物の濃度は2.2重量%であった。
溶媒抽出後の水溶液に活性炭(味の素ファインテクノ社製、商品名CL-K)3.2gを一括で添加し、3℃で1時間攪拌した。この活性炭は、JIS K-1474に従い測定されたヨウ素吸着性能が1550mg/gであり、メチレンブルー吸着性能が310ml/gであった。その後、活性炭を濾別し、水溶液に1Nの水酸化ナトリウム水溶液を加えてpH4.3に調整し、1時間熟成した。この熟成によって式(2)で表される化合物の結晶が析出した。析出した結晶を濾集し、水及びメタノールで結晶を洗浄、乾燥した。得られた結晶の分析結果は以下のとおりであった。尚、下記分析結果中のZ体収率は、以下の計算式により算出した値である。また、第1工程終了後に得られた式(11)の化合物の諸物性を表1に示す。
Z体収率(%)=A×B/C
A;第1工程後に得られた結晶の粗収率(%)
B;式(2)で表される化合物のZ体としての純度(%)
C;フェニル酢酸類除去工程の式(11)で表される化合物の鉱酸塩を基準にした式(1)で表される化合物のZ体の理論収率(%)
(分析結果)
・Z体収率:92.0%
・E体含有率:0.29%
・フェニル酢酸含有率:0.1%
・色調(目視):白色
・1H-NMR(D2O/DCl) ppm
2.52(s、3H)、3.56~3.60(d、1H、18.3Hz)、3.75~3.78(d、1H、18.6Hz)、5.25~5.26(d、1H、5.2Hz)、5.44~5.45(d、1H、5.2Hz)、6.78(s、2H)、9.78(s、1H)
四口フラスコに上記第1工程で得られた式(11)で表される化合物4.0g、式(3)においてXが式(5)及びR1がCH3基である化合物(3a)5.3g、水25g、テトラヒドロフラン25g、トリエチルアミン1.4gを加え、5~10℃で5時間撹拌した。その後、反応液に2.5%炭酸水素ナトリウム水溶液40gを添加してジクロロメタン80gで2回洗浄した。さらに水層に1N塩酸を加えてpH2.0に調整し、30分熟成した。この熟成によって式(7)で表される化合物が析出した。析出した結晶を濾集し、水及びメタノールで結晶を洗浄、乾燥した。得られた結晶の分析結果は以下のとおりであった。また、第2工程終了後に得られたセファロスポリン誘導体の諸物性を表2に示す。
・Z体収率:74.0%
・E体含有率:0.23%
1H-NMR(D2O) ppm
2.27(s、3H)、3.23~3.26(d、1H、18.3Hz)、3.49~3.53(d、1H、18.3Hz)、3.88(s、3H)、5.26~5.27(d、1H、4.6Hz)、 5.73~5.74(d、1H、4.6Hz)、6.19~6.21(d、1H、11.9Hz)、 6.55~6.57(d、1H、11.5Hz)、6.92(s、1H)、8.67(s、1H)
実施例1の第1工程において、活性炭として、味の素ファインテクノ製のCL-KP(商品名)2.8gを用いた以外は、実施例1と同様にして、式(11)で表される化合物の結晶を得た。この活性炭のヨウ素吸着性能は1620mg/gであり、メチレンブルー吸着性能は280ml/gであった。
次いで、実施例1の第2工程と同様に反応後、2.5%炭酸水素ナトリウム水溶液40gを添加してジクロロメタン80gで2回洗浄し、水層を濃縮した。濃縮により式(7)で表される化合物のナトリウム塩が析出した。さらにアセトン50gを加えて0~5℃で30分熟成し、析出した結晶を濾集、水及びアセトンで結晶を洗浄、乾燥した。また、第1工程終了後に得られた式(11)の化合物の諸物性を表1に、第2工程終了後に得られたセファロスポリン誘導体の諸物性を表2に示した。
・Z体収率:67.0%
・E体含有率:0.10%
(1)7位アミド結合の脱保護反応工程
実施例1と同様の操作及び条件で酵素反応を行った。反応終了後、水溶液中には、E体をE体含有率で3.5%含有する式(11)で表される化合物のナトリウム塩が7.0g含まれていた。また、フェニル酢酸がフェニル酢酸含有率で16.6%含まれていた。
(2)フェニル酢酸除去工程(B工程)
第1工程で得られた水溶液から酵素(PGA-450)を濾別し、液温を10℃に保ちながら濃塩酸でpH4.2に調整し、そのまま1時間熟成した。この熟成により式(1)で表される化合物が析出し、次いで濾過して、析出物を回収した。なお、得られた析出物のフェニル酢酸含有率は0.5%であった。
(3)第1工程
340gの水に第2工程で得られた析出物7.0g(Z体6.5g含有)を分散させ、20℃に保ちながら濃硫酸でpH1.0に調整し、該析出物を溶解した。この水溶液に、活性炭として味の素ファインテクノ製のCL-KP(商品名、ヨウ素吸着性能1620mg/g、メチレンブルー吸着性能280ml/g)1.5gを一括で添加し、3℃で1時間撹拌した。その後、活性炭を濾別し、水溶液に1Nの水酸化ナトリウム水溶液を加えてpH4.2に調整し、1時間熟成した。この熟成によって式(11)で表される化合物の結晶が析出した。析出した結晶を濾集し、水及びメタノールで結晶を洗浄、乾燥した。また、第1工程終了後に得られた式(11)の化合物の諸物性を表1に示した。
(4)第2工程
実施例2と同様な操作を実施し、式(7)で表される化合物のナトリウム塩を得た。また、第2工程終了後に得られたセファロスポリン誘導体の諸物性を表2に示した。
実施例1の7位アミド結合の脱保護反応工程と同様にして酵素反応を行い、得られた式(11)で表される化合物のナトリウム塩を含有する水溶液から酵素を濾別した。濾液の全量を、液温20℃に保ちながら濃塩酸でpH0.9に調整した。これによって式(11)で表される化合物の塩酸塩の水溶液を得た。次いで、この水溶液に実施例1の第1工程で用いた活性炭に代えてJIS K-1474に従い測定されたヨウ素吸着性能が1080mg/gであり、メチレンブルー吸着性能が180ml/gである活性炭(味の素ファインテクノ社製、商品名SD-2)5.6gを一括で添加し、3℃で1時間攪拌した。活性炭処理後のフェニル酢酸含有率は1.1%であった。その後、活性炭を濾別し、得られた全量の濾液に対し、実施例1の第2工程と同様にして溶媒抽出を行った。溶媒抽出後の水溶液に1Nの水酸化ナトリウム水溶液を加えてpH4.3に調整し、1時間熟成した。この熟成によって式(11)で表される化合物の結晶が析出した。析出した結晶を濾集し、水及びメタノールで結晶を洗浄、乾燥した。また、第1工程終了後に得られた式(11)の化合物の諸物性を表1に示した。
(第2工程)
実施例2と同様な操作を実施し、式(7)で表される化合物のナトリウム塩を得た。また、第2工程終了後に得られたセファロスポリン誘導体の諸物性を表2に示した。
比較例1の第1工程で用いたものと同じ活性炭(SD-2)3.2gを一括で添加し、3℃で1時間攪拌した以外は、(1)7位アミド結合の脱保護反応工程、(2)フェニル酢酸除去工程を実施し、式(11)で表される化合物の結晶を得た。また、第1工程終了後に得られたセファロスポリン誘導体の諸物性を表1に示した。
(第2工程)
実施例2と同様な操作を実施し、式(7)で表される化合物のナトリウム塩を得た。また、第2工程終了後に得られたセファロスポリン誘導体の諸物性を表2に示した。
(1)第3工程
実施例2で得られた式(7)で表される化合物のナトリウム塩4.5gをジメチルホルムアミド(DMF)25gに溶解し、ピバリン酸クロロメチル(1.39g)とヨウ化ソーダ(1.39g)を用いて調製したピバリン酸ヨードメチルのDMF溶液25mlを0~5℃で添加し、その温度で1時間撹拌した。その後、反応液に酢酸エチル200gを加え、100gの水で3回洗浄した。続いて結晶が析出し始めるまで濃縮し、n-ヘキサン100gを加えて0~5℃で1時間熟成した。熟成終了後、結晶を濾集、n-ヘキサンで洗浄し、乾燥し7-[2-メトキシイミノ-2-(2-アミノチアゾール-4-イル)アセトアミド]-3-[2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸ピバロイルオキシメチルエステル(セフジトレンピボキシル)の淡黄白色結晶を得た。
HPLC純度97.8%(分析方法は「第十五改正日本薬局方(第一追補)」、平成19年9月28日、厚生労働省 告示316号、セフジトレン ピポキシルの項参照。)
Claims (7)
- 下記式(1)で表される7-アミノ-3-[(E/Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はそのアルカリ金属塩の水溶液を、JIS K-1474に従い測定されたヨウ素吸着性能が1200mg/g以上であり、メチレンブルー吸着性能が250ml/g以上である活性炭と接触させて、下記式(2)で表される7-アミノ-3-[(Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はそのアルカリ金属塩の含有率が向上した式(1)で表される7-アミノ-3-[(E/Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はそのアルカリ金属塩を得る第1工程、
次いで、前記第1工程で得られた一般式(2)で表される7-アミノ-3-[(Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はそのアルカリ金属塩の含有率が向上した式(1)で表される7-アミノ-3-[(E/Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はそのアルカリ金属塩と、下記一般式(3)で表される化合物とを反応させる第2工程を含むことを特徴とする下記一般式(4a)で表されるセファロスポリン誘導体又はそのアルカリ金属塩の製造方法。
(式中、R1は、アルキル基を示す。Xは活性エステル基を示す。) - 前記式(1)で表される化合物を、鉱酸で処理して鉱酸塩となし、該鉱酸塩を含む低pH領域の前記水溶液を前記活性炭と接触させる請求項1又は2記載の製造方法。
- 前記鉱酸が塩酸である請求項3記載の製造方法。
- 前記活性炭で処理した後の処理液のpHを3.8~4.8に調整して、式(2)で表される化合物の結晶を沈殿させる請求項1乃至4のいずれかに記載の製造方法。
- 前記式(1)で表される7-アミノ-3-[(E/Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はそのアルカリ金属塩の水溶液が、下記一般式(6)で表される7-置換アシルアミノ-3-[(E/Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸の塩を酵素反応に付して7位アミド結合の脱保護反応を行い、該脱保護反応の副生成物であるフェニル酢酸又はその誘導体を含んだ前記一般式(1)で表される7-アミノ-3-[(E/Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はその塩の水溶液を得た後、下記(A)又は(B)の何れかの処理工程を行ったものである請求項1乃至5記載の製造方法。
(A)得られる前記式(1)で表される7-アミノ-3-[(E/Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はその塩の水溶液に対し、有機溶媒を用いて、前記フェニル酢酸又はその誘導体の抽出処理を行う工程。
(B)得られる前記式(1)で表される7-アミノ-3-[(E/Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はその塩の水溶液から該7-アミノ-3-[(E/Z)-2-(4-メチルチアゾール-5-イル)ビニル]-3-セフェム-4-カルボン酸又はその塩を析出させる晶析処理を行う工程。
(式中、R3はベンジル基、フェノキシメチル基を示す。Mは一価のカチオンを示す。)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011551861A JPWO2011093294A1 (ja) | 2010-01-27 | 2011-01-26 | セファロスポリン誘導体の製造方法 |
CN2011800074870A CN102725297A (zh) | 2010-01-27 | 2011-01-26 | 头孢菌素衍生物的制造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010016053 | 2010-01-27 | ||
JP2010-016053 | 2010-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011093294A1 true WO2011093294A1 (ja) | 2011-08-04 |
Family
ID=44319281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/051390 WO2011093294A1 (ja) | 2010-01-27 | 2011-01-26 | セファロスポリン誘導体の製造方法 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2011093294A1 (ja) |
CN (1) | CN102725297A (ja) |
WO (1) | WO2011093294A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103665002A (zh) * | 2013-12-18 | 2014-03-26 | 成都医路康医学技术服务有限公司 | 一种头孢妥仑匹酯的制备方法 |
WO2016068330A1 (ja) * | 2014-10-30 | 2016-05-06 | 三栄源エフ・エフ・アイ株式会社 | ゲニポシド、ゲニピン、又はこれらの両方を除去する方法 |
US11932814B2 (en) | 2021-04-27 | 2024-03-19 | Carbon Technology Holdings, LLC | Biocarbon blends with optimized fixed carbon content, and methods for making and using the same |
US11959038B2 (en) | 2011-04-15 | 2024-04-16 | Carbon Technology Holdings, LLC | High-carbon biogenic reagents and uses thereof |
US11987763B2 (en) | 2021-07-09 | 2024-05-21 | Carbon Technology Holdings, LLC | Processes for producing biocarbon pellets with high fixed-carbon content and optimized reactivity, and biocarbon pellets obtained therefrom |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106366097A (zh) * | 2016-08-19 | 2017-02-01 | 陕西思尔生物科技有限公司 | 一种头孢妥仑匹脂的制备方法 |
CN109180704B (zh) * | 2018-11-19 | 2020-06-05 | 齐鲁安替制药有限公司 | 一种头孢妥仑匹酯的合成方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61178991A (ja) * | 1984-09-07 | 1986-08-11 | Meiji Seika Kaisha Ltd | 新規セフアロスポリン化合物 |
WO2005003141A2 (en) * | 2003-07-04 | 2005-01-13 | Orchid Chemicals & Pharmaceuticals Ltd | An improved process for the preparation of cefditoren |
JP2005343854A (ja) * | 2004-06-04 | 2005-12-15 | Meiji Seika Kaisha Ltd | 3−アルケニルセフェム化合物の製造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6219593A (ja) * | 1985-07-18 | 1987-01-28 | Meiji Seika Kaisha Ltd | 新規セフエム化合物 |
DK0658558T3 (da) * | 1993-11-17 | 2001-04-17 | Biochemie Gmbh | Adskillelse af cephalosporinisomere |
WO2005016936A2 (en) * | 2003-08-14 | 2005-02-24 | Ranbaxy Laboratories Limited | Process for selective preparation of z-isomer of cefditoren and pharmaceutically acceptable salts and esters thereof |
WO2005100369A1 (en) * | 2004-04-13 | 2005-10-27 | Ranbaxy Laboratories Limited | Depletion of e-isomers in preparation of z-enriched 3-(2-substituted vinyl) cephalosporins |
-
2011
- 2011-01-26 CN CN2011800074870A patent/CN102725297A/zh active Pending
- 2011-01-26 WO PCT/JP2011/051390 patent/WO2011093294A1/ja active Application Filing
- 2011-01-26 JP JP2011551861A patent/JPWO2011093294A1/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61178991A (ja) * | 1984-09-07 | 1986-08-11 | Meiji Seika Kaisha Ltd | 新規セフアロスポリン化合物 |
WO2005003141A2 (en) * | 2003-07-04 | 2005-01-13 | Orchid Chemicals & Pharmaceuticals Ltd | An improved process for the preparation of cefditoren |
JP2005343854A (ja) * | 2004-06-04 | 2005-12-15 | Meiji Seika Kaisha Ltd | 3−アルケニルセフェム化合物の製造方法 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11959038B2 (en) | 2011-04-15 | 2024-04-16 | Carbon Technology Holdings, LLC | High-carbon biogenic reagents and uses thereof |
US11965139B2 (en) | 2011-04-15 | 2024-04-23 | Carbon Technology Holdings, LLC | Systems and apparatus for production of high-carbon biogenic reagents |
CN103665002A (zh) * | 2013-12-18 | 2014-03-26 | 成都医路康医学技术服务有限公司 | 一种头孢妥仑匹酯的制备方法 |
CN103665002B (zh) * | 2013-12-18 | 2016-02-03 | 成都医路康医学技术服务有限公司 | 一种头孢妥仑匹酯的制备方法 |
WO2016068330A1 (ja) * | 2014-10-30 | 2016-05-06 | 三栄源エフ・エフ・アイ株式会社 | ゲニポシド、ゲニピン、又はこれらの両方を除去する方法 |
JPWO2016068330A1 (ja) * | 2014-10-30 | 2017-08-10 | 三栄源エフ・エフ・アイ株式会社 | ゲニポシド、ゲニピン、又はこれらの両方を除去する方法 |
US10611914B2 (en) | 2014-10-30 | 2020-04-07 | San-Ei Gen F.F.I., Inc. | Method for removing geniposide or genipin or both |
US11072709B2 (en) | 2014-10-30 | 2021-07-27 | San-Ei Gen F.F.I., Inc. | Method for removing geniposide or genipin or both |
US11932814B2 (en) | 2021-04-27 | 2024-03-19 | Carbon Technology Holdings, LLC | Biocarbon blends with optimized fixed carbon content, and methods for making and using the same |
US11987763B2 (en) | 2021-07-09 | 2024-05-21 | Carbon Technology Holdings, LLC | Processes for producing biocarbon pellets with high fixed-carbon content and optimized reactivity, and biocarbon pellets obtained therefrom |
Also Published As
Publication number | Publication date |
---|---|
CN102725297A (zh) | 2012-10-10 |
JPWO2011093294A1 (ja) | 2013-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011093294A1 (ja) | セファロスポリン誘導体の製造方法 | |
CA2124322C (en) | Process for the purification of a 3-cephem-4-carboxylic acid derivative | |
FR2517308A1 (fr) | Procede de preparation de derives de 3-alcoxymethylcephalosporines | |
WO2005003141A2 (en) | An improved process for the preparation of cefditoren | |
KR100515273B1 (ko) | 3-(2-치환-비닐)-세파로스포린의 z-이성체의 선택적제조방법 | |
EP1752459B1 (en) | Process for production of 3-alkenylcephem compounds | |
US20070111980A1 (en) | Process for preparing pure cephalosporine intermediates | |
JPH05132488A (ja) | 新規セフアロスポリン誘導体 | |
JP4705199B2 (ja) | 3−アルケニルセフェム化合物の製造方法 | |
JP4659074B2 (ja) | 3−アルケニルセフェム化合物の製造方法 | |
JPH064646B2 (ja) | 新規セフアロスポリン誘導体 | |
KR101618874B1 (ko) | 3-알케닐세펨 화합물의 제조 방법 | |
CN108299470B (zh) | 一种头孢特仑新戊酯的制备方法 | |
EP2723882B1 (en) | Process for preparing 3'-thiosubstituted cephalosporins employing a penicillin g acylase | |
CN113185538B (zh) | 一种头孢泊肟酸的制备方法 | |
EP1029864B1 (en) | Process for the purification of a 3-cephem-4-carboxylic acid derivative | |
US20150112057A1 (en) | Novel crystalline cefoperazone intermediate | |
WO2012175587A2 (en) | Novel crystalline cefoperazone intermediate | |
US20070083042A1 (en) | Processes for the preparation of cephalosporin derivatives | |
JP2002053568A (ja) | アミドチアゾール酢酸誘導体の製造方法 | |
JPS6310708B2 (ja) | ||
CN110590812A (zh) | 一种头孢米诺钠的制备方法 | |
JP2002234893A (ja) | 3−(2−置換−ビニル)−セファロスポリンのz異性体の選択的な製造方法 | |
WO2005042543A1 (en) | Processes for the preparation of cephem derivatives | |
JPS5913787A (ja) | セフアロスポリン化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180007487.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11737007 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011551861 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6579/CHENP/2012 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11737007 Country of ref document: EP Kind code of ref document: A1 |